Theranica

Happy Holidays from Theranica! As we wrap up another incredible year, we want to take a moment to extend our heartfelt gratitude to our healthcare community, patients, partners, and team. Your trust and unwavering support have been essential in driving our mission to advance treatment options for those living with migraine disease. Together, we’ve made significant strides in transforming care and expanding access for all. Thank you for being part of our mission to advance treatment and access for those with migraine disease. This holiday season, we wish you and your loved ones peace, joy, and good health. Here’s to a bright and healthy 2025!

Despite FDA clearance for both acute and preventive treatment in ages 8 and up, along with the abundance of clinical evidence in peer-reviewed journals, only a limited number of insurance providers currently cover the Nerivio® REN wearable, leaving many people living with migraine disease without affordable access to this essential non-drug therapy. Help the many living with migraine close this gap. Join the effort to advocate for broader insurance coverage of the REN wearable, so more children, adolescents, and adults can access effective migraine treatment without relying on medication. Whether you’re a pediatrician, headache specialist, or neurologist, follow Theranica’s LinkedIn page to learn more about how you can advocate for your patients and help expand access to care.

The Nerivio® REN wearable: a non-drug, non-disruptive migraine treatment option for adolescents. In a real-world study involving adolescents, REN was shown to be an effective, safe, and well-tolerated treatment for acute migraine.[1] Among 1,629 adolescents studied, consistent response in at least 50% of treatments at two hours post-treatment demonstrated: - 60.3% experienced pain relief - 26.3% achieved pain freedom - 66.3% experienced relief from functional disability - 41.2% achieved freedom from functional disability - 83% of patients achieved these results without needing to take a prescription drug therapy The REN wearable is FDA-indicated for both acute and preventive migraine treatment in patients aged 8 years and above, empowering patient populations like adolescents, to manage their migraine without the need for traditional medication. Learn more at Nerivio.com —------------------------------------------------------ 1. Esparham et al, “Acute Treatment of Migraine in Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)”, 2023.

Childhood and adolescent migraine: A growing concern with lifelong implications. Migraine isn’t just a debilitating disease that affects adults, it also impacts 1 in 10 children.[1] The burden on young people is also alarming, as migraine disease affects their overall quality of life.[2] Early intervention is critical. If left untreated, migraine that starts in childhood often worsens into adulthood, increasing the likelihood of chronic migraine.[3] That’s where the Nerivio® REN wearable comes in. As the only FDA-cleared, drug-free acute and preventive migraine treatment for ages 8+, the Nerivio REN wearable can serve as a first-line therapy for children and adolescents living with migraine. It empowers young patients to take an active role in managing their migraine disease. Together, we can improve outcomes and help children and adolescents thrive without the weight of debilitating migraine attacks. Learn more about how the REN wearable can help children as young as 8 years old manage their migraine symptoms at nerivio.com —----------------------------------------- 1. Khalil et al, “Migraine Headache in Childhood”, 2023.  2. Chen et al, “Global, regional, and national burden and trends of migraine among youths and young adults aged 15–39 years from 1990 to 2021: findings from the global burden of disease study 2021”, 2024.  3. Gazerani, Parisa “Migraine and Mood in Children”, 2021.

We’re proud that the Nerivio® REN wearable is now FDA-cleared for the treatment of migraine in children aged 8 and up! As the first non-drug, FDA-cleared wearable for both acute and preventive migraine treatment, the REN wearable has already established safety and efficacy in treating migraine disease in adolescents 12+. Now, children as young as 8 can benefit from this innovative treatment. Migraine disease affects about 1 in 10 children, which can significantly impair school performance and quality of life.[1] This impact on quality of life is similar to that of other chronic diseases like arthritis and cancer.[2] Early intervention is essential to preventing long-term disability.[3] The Nerivio REN wearable is transforming migraine care for younger patients, offering a safe, dual-use, and drug-free treatment option. Learn more here: https://lnkd.in/g7RQ4smm —----------------------------------------------- 1. Khalil et al, “Migraine Headache in Childhood”, 2023.  2. Powers et al, “Quality of Life in Childhood Migraines: Clinical Impact and Comparison to Other Chronic Illnesses”, 2008. 3. Gazerani, Parisa “Migraine and Mood in Children”, 2021.

For veterans, understanding the intersection of migraine disease, traumatic brain injury (TBI), and psychiatric conditions is crucial for improving their healthcare outcomes.[1] By acknowledging the full spectrum of these symptoms and how they interact, we can deliver more tailored care and reduce the burden on veterans living with these challenges. The Nerivio® REN wearable is a non-drug, FDA-cleared treatment for migraine, which allows veterans to manage their disease without interfering with medications they may be taking for TBI, chronic pain, or mental health conditions, and does not contribute to medication overuse headaches (MOH). Better yet, it’s covered under VA benefits, providing safe and dual-use care for those who need it most. Learn more at https://lnkd.in/eJYX2SwB —---------------------------------------------- 1. Herbert et al, “Cognitive symptoms in veterans with migraine or traumatic brain injury: A Million Veteran Program study”, 2024.

Today marks a new milestone in migraine treatment: We’ve reached 1 million treatments for patients using the Nerivio® REN wearable to treat migraine disease! This achievement reflects the impact we’re making, particularly for patient populations like children and adolescents living with migraine disease, offering a drug-free, safe, and non-disruptive treatment option. Thank you to our dedicated community of patients, healthcare providers, and partners who trust the REN wearable as an essential treatment in managing migraine disease. This milestone is just the beginning. Here’s to the next million REN treatments! Read the full press release here: https://lnkd.in/gBWNc2fc

Migraine disease affects 10 percent of children, putting them at a higher risk of developing chronic migraine into adulthood if left untreated.[1] For children and adolescents, managing migraine effectively is crucial. The good news: The Nerivio® REN wearable is now indicated for children as young as 8 years old, providing both acute and preventative migraine treatment. Follow Theranica to discover how the REN wearable can make a difference in the treatment of migraine, especially for children and adolescents.  —---------------------------------------------- 1. Gazerani, Parisa “Migraine and Mood in Children”, 2021.

This Thanksgiving, we want to extend our heartfelt gratitude to healthcare providers, patients, families, and partners. You inspire us every day in our mission to prevent the 1 in 10 children with migraine disease from becoming adults with uncontrolled migraine, to avoid long-term disability and compromised quality of life.[1] We are truly thankful for the opportunity to bring the Nerivio® REN wearable to those who need it most, helping them manage migraine safely and effectively. With the REN wearable, we hope to make it easier for people to focus on what matters most—family, friends, and cherished moments. Wishing everyone a happy, healthy, and abundant Thanksgiving! Learn more here: Nerivio.com  —-------------------------------------------------- 1. Khalil et al, “Migraine Headache in Childhood”, 2023.

In case you missed it: the FDA recently cleared the Nerivio® REN wearable for children aged 8+, building on Nerivio's established efficacy and safety in acute and preventive treatment of migraine disease in adults and adolescents 12+. This milestone addresses a critical need in ages 8 and up: providing a safe, non-drug option for children with migraine disease. With this expanded FDA clearance, children ages 8 and up now have a treatment option available that’s not only effective but also non-disruptive to their daily lives, helping them stay engaged in school and activities. Unlike traditional treatments, the Nerivio® REN wearable offers a drug-free option with no pills to swallow, no risks of drug-to-drug interactions, and no concerns about dosage based on weight. This expanded indication empowers this population of patients and gives them a treatment option that reshapes the landscape of pediatric migraine care. Learn more here: https://nerivio.com/